Human Papillomavirus Vaccine Market Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2025

Mar 2018| TMR327A| Transparency

Report Highlights

Human Papillomavirus Vaccine Market: Overview

This report on the global human papillomavirus vaccine market analyzes the current and future scenario of the global market. Rise in private and public funding for human papillomavirus vaccine, increase in government initiatives to prevent cervical cancer caused by human papillomavirus, growth in prevalence of various cancers caused by human papillomavirus are expected to drive the market during the forecast period.

The global human papillomavirus vaccine market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments.  It also provides information and data analysis of the global market with respect to segments based on valance, indication, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints, opportunities, and trends have been provided in the market overview section.  Additionally, the section comprises pipeline analysis to help understand the scope in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus providing a thorough analysis of the overall competitive scenario in the global human papillomavirus vaccine market.

In terms of valence, the market has been divided into Bivalent and Quadrivalent – nonavalent. Quadrivalent, and nonavalent segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by bivalent segment. Launch of new multivalent human papillomavirus and increase in incidences of cervical cancer are likely to propel the segment. Based on indication type, cervical cancer dominated the market, in terms of revenue generated, in 2016 and is anticipated to continue its dominance during the forecast period. Anal cancer was the second largest segment in 2016 and it is likely to continue this trend from 2017 to 2025. In terms of distribution channel, government entities held a dominant share of the market. However, it is anticipated to lose market share during the forecast period owing to public and private alliances such as GAVI that are focused on vaccinating people in developing countries.

Geographically, the global human papillomavirus vaccine market has been categorized into major regions and key countries in the respective regions: North America (the US  and Canada), Europe (Germany, France, Italy, Spain, the UK, and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa).  

The report also profiles major players operating in the global human papillomavirus vaccine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments.  Major players profiled in this report include Merck & Co., Inc., GlaxoSmithKline plc. Sanofi, Johnson & Johnson, AstraZeneca, and Serum Institute of India Pvt. Ltd.

The global human papillomavirus vaccine market has been segmented as below:

Global Human Papillomavirus Vaccine Market, by Valence

Quadrivalent and Nonavalent

Global Human Papillomavirus Vaccine Market, by Indication

Cervical Cancer
Anal Cancer
Vaginal Cancer
Penile Cancer
Vulvar Cancer
Oropharyngeal Cancer
Genital Warts

Global Human Papillomavirus Vaccine Market, by Distribution Channel

Physician Distributors
Government Entities
Public and Private Alliances

Global Human Papillomavirus Vaccine Market, by Geography

North America
Rest of Europe
Asia Pacific
Australia & New Zealand
Rest of Asia Pacific
Latin America
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report